AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Rhea-AI Summary

AIM ImmunoTech (OTC Pink: AIMI), an immuno-pharma company specializing in therapeutics for cancers, immune disorders, and viral diseases including COVID-19, has announced its transition to trading under the ticker AIMI on the Pink Open Market effective April 07, 2025.

The company also confirmed its upcoming Special Meeting scheduled for April 30, 2025, where a reverse split proposal will be discussed. Shareholders can find detailed information in AIM's Definitive Proxy Statement filed on April 2, 2025.

Positive

• None.

Negative

• Trading moved to Pink Open Market, indicating potential delisting from major exchanges
• Pending reverse stock split proposal suggests potential share price concerns

OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on.

For additional information, refer to AIM’s Definitive Proxy Statement filed April 2, 2025.

About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What is AIM ImmunoTech's new stock ticker symbol on the Pink Open Market?

AIM ImmunoTech's new stock ticker symbol is AIMI, effective April 07, 2025.

When is AIM ImmunoTech's Special Meeting to discuss the reverse split?

The Special Meeting is scheduled for April 30, 2025.

What therapeutic areas does AIM ImmunoTech focus on?

AIM focuses on therapeutics for multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

When did AIM ImmunoTech file its Definitive Proxy Statement for the reverse split meeting?

AIM filed its Definitive Proxy Statement on April 2, 2025.